AnaptysBio tumbles after latest legal battle over cancer drug
21/11/2025 13:51
** Shares of drug developer AnaptysBio ANAB.O tumble 14.5% to $32.21 premarket ** GSK's GSK.L oncology unit, Tesaro, sued AnaptysBio late Thursday, claiming the biotech breached a 2014 license deal for cancer drug Jemperli ** Tesaro wants to terminate the agreement, cut royalties by half, and secure permanent rights to Jemperli ** AnaptysBio countersued on Friday, accusing Tesaro of breaking exclusivity rules and favoring other GSK drugs over Jemperli ** Both sides have sought an expedited trial in Delaware, expected in July 2026 ** In 2020, AnaptysBio sued GSK over similar exclusivity concerns ** Up to last close, stock up ~184% YTD (Reporting by Sahil Pandey in Bengaluru) ((Sahil.Pandey@thomsonreuters.com))
Recent news on AnaptysBio
See all newsU.S. RESEARCH ROUNDUP- Applied Materials, NVIDIA, Thermo Fisher Scientific
AnaptysBio's Q1 collaboration revenue falls, net loss widens
Brief: AnaptysBio Q1 Net Income USD -52.884 Million
Brief: Anaptys Appoints Chris Murphy As Chief Financial Officer And Owen Hughes To Board Of Directors
Brief: GSK Says Unit Tesaro's Claim For Declaratory Judgment Against Anaptysbio Unchanged